Remyelination therapies, which are currently under development, have a great potential to
delay, prevent or even reverse disability in multiple sclerosis patients. Several models are …

Fingolimod is a well-tolerated, highly effective disease-modifying therapy successfully
utilized in the management of multiple sclerosis. The active metabolite, fingolimod …

Diabetic retinopathy is a major retinal disease and a leading cause of blindness in the world.
Diabetic retinopathy is a neurovascular disease that is associated with disturbances of the …

Pathogenic changes to TAR DNA-binding protein 43 (TDP-43) leading to alteration of its
homeostasis are a common feature shared by several progressive neurodegenerative …

Despite the anatomical separation, strong evidence suggested a bidirectional association
between gut microbiota and central nervous system. Cross-talk between gut microbiota and …

Spinal cord injury (SCI) is a leading cause of morbidity and disability in the world. Over the
past few decades, the exact molecular mechanisms describing secondary, persistent …

The imbalance in sphingolipid signaling may be critically linked to the upstream events in
the neurodegenerative cascade of Alzheimer's disease (AD). We analyzed the influence of …

Siponimod, which is approved to treat active secondary progressive multiple sclerosis, acts
as a functional antagonist of sphingosine-1-phosphate (S1P) receptor 1 (S1P 1) and an …

Metal-organic frameworks (MOFs) are known as potential pharmaceutical carriers because
of their structure. Here, we evaluated the sub-acute administrations of MOF-5 on behavioral …

Background Fingolimod (FTY720) is an oral immunosuppressive compound that has been
prescribed to multiple sclerosis (MS) patients since 2010. The lipophilicity and low molecular …